Adicet Bio Inc
Research Adicet Bio Inc (ACET) on Bullrun: market cap USD 84.25M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerACET
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 84.25M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 21.36M
- Free cash flow-USD 20.03M
Valuation Snapshot
latest market cap is USD 84.25M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 116.80M | -USD 96.98M | n/a | -16.95 | USD 38.92M | USD 14.74M | USD 159.21M |
| FY2024 | USD 0 | -USD 117.12M | -USD 93.50M | n/a | -21.33 | USD 56.50M | USD 17.23M | USD 186.61M |
| FY2023 | USD 0 | -USD 142.66M | -USD 98.18M | n/a | -3.31 | USD 159.71M | USD 20.92M | USD 170.18M |
| FY2022 | USD 24.99M | -USD 69.79M | -USD 61.55M | n/a | -1.7 | USD 257.66M | USD 22.39M | USD 292.34M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 84.25M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 80.83M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 79.42M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 81.58M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 383.09M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 695.01M | n/a | n/a | n/a |
About Adicet Bio Inc
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Adicet Bio Inc's market cap?
Adicet Bio Inc's market capitalization is USD 84.25M.
What does Adicet Bio Inc do?
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in Boston, Massachusetts.